-
Mashup Score: 2
Investigators are evaluating the efficacy and safety of APG-157 for patients with head and neck cancer in a phase 2 clinical trial.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted FTD to reversibly active ADC, ozuriftamab vedotin, for patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have previously progressed on anti–PD-1 or anti–PD-L1 therapies. #hncsm https://t.co/PO4SmRfCnH https://t.co/XuaayzcqZG
-
-
Mashup Score: 0
Results from a phase 1 trial evaluating the CAR T-cell therapy, AIC100, in relapsed/refractory thyroid cancer support the FDA’s RMAT designation.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has designated AIC100 for treatment in recurrent anaplastic thyroid cancer, Regenerative Medicine Advanced Therapy status. #hncsm | @FDAOncology @US_FDA https://t.co/lkhgR5Tc6T
-
-
Mashup Score: 0Nintedanib Does Not Significantly Improve PFS in Thyroid Cancer - 8 month(s) ago
An observed extension in progression-free survival with nintedanib vs placebo did not warrant continued development of the therapy for thyroid cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Nintedanib did not show a clinically significant improvement in PFS vs placebo in patients with radioiodine refractory differentiated thyroid cancer and medullary thyroid cancer. #hncsm https://t.co/4V0L5gxph3
-
-
Mashup Score: 1Limiting Complete Thyroidectomy Post Hemithyroidectomy, Total Thyroidectomy May Reduce Overtreatment in Thyroid Cancer - 9 month(s) ago
Retrospective results found considering conservative initial surgery options can reduce overtreatment for patients with thyroid cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Overtreatment may be reduced for patients with thyroid cancer by limiting completion thyroidectomy after hemithyroidectomy, total thyroidectomy, and revision surgery after total thyroidectomy. #hncsm https://t.co/sAs1bdKxLh
-
-
Mashup Score: 0
Phase 3 results show that treatment with vandetanib had no statistically significant improvement in PFS and more adverse effects than placebo.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A median PFS of 10.0 months (95% CI, 6.0-11.1) occurred in the vandetanib group and 5.7 months (95% CI, 5.5-8.4) in the placebo arm. #hncsm https://t.co/jpfvCVpuOj
-
-
Mashup Score: 1Dr Wirth on Questions About Selpercatinib Use in Advanced RET Fusion+ Thyroid Cancer - 9 month(s) ago
Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib. @MGHCancerCenter #hncsm https://t.co/fdc5uRBX2e
-
-
Mashup Score: 12
The cetuximab trials provide indirect data suggesting that the differences between cisplatin schedules are subtle.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
We had a fun time with this "back of the napkin" comparison of bolus vs. weekly cisplatin using the cetuximab trials. The quick hit is we should all have equipoise to enroll to NRG HN009! #hncsm @LevineCancer @NRGonc https://t.co/YOlUCeu0JN https://t.co/1pg48JHDgu
-
-
Mashup Score: 0
A phase 2 study suggests that combining nivolumab with reirradiation may be safe and effective for patients with recurrent or second primary head and neck squamous cell carcinoma.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet-
A phase 2 study suggests that combining nivolumab with reirradiation may be safe and effective for patients with recurrent or second primary head and neck squamous cell carcinoma. #hncsm https://t.co/G55MtBbclP
-
-
Mashup Score: 1Selpercatinib Earns Full FDA Approval Status in RET+ Thyroid Cancer - 10 month(s) ago
Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
.@US_FDA gives traditional approval to selpercatinib for RET fusion-positive thyroid cancer. #hncsm https://t.co/OYjtKyJotZ https://t.co/4LQcJfCNZY
-
The FDA has granted fast track designation to the investigational immune-oncology agent, APG-157, as a neoadjuvant treatment for patients with head and neck cancer. #hncsm | @US_FDA @FDAOncology https://t.co/A6nHkqiyIF